PF 04217329: Clinical Trials

2 trials of PF 04217329, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 completed. 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 22Completed 2

Follow PF 04217329: new trials by email Literature Review of PF 04217329 trials Research Report on PF 04217329

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Phase 2 Study Of The 24-Hour Intraocular Pressure Lowering And Systemic Exposure Of PF-04217329
PF-04217329, latanoprost vehicle, latanoprost - Glaucoma, Open-Angle, Ocular Hypertension
Phase 2CompletedPfizer312010-01-012021-05-03
Safety and Efficacy of PF-04217329 in Patients With Glaucoma or Elevated Eye Pressure.
PF-04217329 - Lowest Dose, PF-04217329 - Low Dose, PF-04217329 - Middle Dose - Primary Open-Angle Glaucoma, Ocular Hypertension
Phase 2CompletedPfizer3182007-12-112021-04-30

Conditions studied

Glaucoma, Open-Angle (2)  ·  Ocular Hypertension (2)

Sponsors

Pfizer (2)

Countries

United States (2)

Results publications

PMID 21851167